CIRCULOGENE

HEMATOLOGICAL TESTING

One Tube
One Week
Complete Results

MYELODYSPLASTIC SYNDROMES (MDS)

- Several studies have indicated that >80% of patients with MDS harbor at least 1 somatic mutation suggestive of clonal hematopoiesis.
- NCCN Guidelines® identify mutations in key genes frequently associated with MDS which may be useful in differential diagnosis and prognostic stratification.

Circulogene MDS	
CDKN2A	JAK2
EZH2	NRAS
IDH1	TP53
IDH2	

ACUTE MYELOID LEUKEMIA (AML)

- NCCN Guidelines® recognize the clinical utility of multiplex gene panels for assessment of additional mutations as prognostic indicators in AML, to guide therapy, and eligibility for clinical trials.
- Two mutations are specifically used to predict response to novel targeted treatments:
  - FLT3 for midostaurin in newly diagnosed AML
  - IDH2 for enasidenib in relapsed, refractory AML

Circulogene AML	
ABL1	KRAS
CDKN2A	NPM1
EZH2	NRAS
FLT3	PDGFRA
IDH1	PTEN
IDH2	PTPN11
JAK3	TP53
KIT	

MYELOPROLIFERATIVE NEOPLASMS (MPN)

- Somatic mutations in ABL1, JAK2, and MPL have been identified in patients suspected of having MPN and are now used for diagnosis of these diseases. Ruxolitinib, a JAK2 inhibitor, has been approved by the FDA to treat polycythemia vera (PV).
- Other mutations are recognized by NCCN® as having prognostic significance in MPN.
- The incorporation of NGS platforms into the clinical management of MDS/AML/MPN syndromes is likely to play an integral role in the diagnosis, prognosis, and treatment of this unique group of complex hematologic malignancies.

Circulogene MPN	
ABL1	IDH1
BRAF	IDH2
EZH2	JAK2
FBXW7	MPL

CIRCULOGENE
3125 Independence Drive, Suite 301
Birmingham, Alabama 35209

CIRCULOGENE.COM
1.855.614.7083
INFO@CIRCULOGENE.COM